In addition to tumor size, tumor number, differentiation, and vascular invasion, we found that the promoter II+III haplotype was an independent prognostic factor for TTR and OS (TTR: HR = 1.83, 95% CI = 1.61−2.25, p<0.001; OS: HR = 1.92, 95% CI = 1.78−2.93, p<0.001] (Table 2). This evidence concerns the gene TTR and neoplasm.